Kazia Therapeutics receives full regulatory approval for EVT801 phase 1 studyProactive Investors • 09/02/21
Kazia Therapeutics directors support oncology-focused drug strategy with on-market purchasesProactive Investors • 08/30/21
Kazia Therapeutics eyeing commercialisation revenue after “game-changing” FY21Proactive Investors • 08/26/21
Kazia Therapeutics has 'busy and productive' June quarter with important readouts slated for second halfProactive Investors • 07/30/21
Kazia Therapeutics makes strong progress with clinical programs for paxalisib and EVT801Proactive Investors • 06/30/21
Kazia Therapeutics lands key manufacturing patents for paxalisib in US and IndiaProactive Investors • 06/24/21
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for GlioblastomaPRNewsWire • 06/15/21
Kazia Therapeutics to collaborate with Cornell University for new paxalisib phase II clinical trialProactive Investors • 06/15/21
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First PatientPRNewsWire • 06/07/21
Kazia Therapeutics study of paxalisib in primary CNS Lymphoma at Dana-Farber enrols first patientProactive Investors • 06/07/21
Kazia Therapeutics directors demonstrate confidence in bio-tech strategy with on-market purchasesProactive Investors • 06/02/21
Kazia Therapeutics directors demonstrate confidence in company with on-market purchasesProactive Investors • 05/04/21
Kazia Therapeutics lands trifecta of licensing deals in March quarter, leaving it "a vastly stronger and more substantial business"Proactive Investors • 04/30/21
Kazia Therapeutics' EVT801 deal secures price target of A$2.60 from Corporate Connect and BUY rating from HC WainwrightProactive Investors • 04/26/21
Kazia Therapeutics valuation lifts off the back of in-licensing of EVT901 drug: Edison GroupProactive Investors • 04/20/21
Kazia Therapeutics licenses global rights to novel, first-in class, clinic-ready oncology drug candidate EVT801Proactive Investors • 04/20/21
Kazia Therapeutics halted with potential in-licensing transaction announcement pendingProactive Investors • 04/16/21
Kazia Therapeutics licensing deals result in A+ rating and $2.60 price target from Corporate ConnectProactive Investors • 04/14/21
Kazia Therapeutics to present pharmacokinetic data from Paxalisib Phase II study at prestigious AACR annual meetingProactive Investors • 04/09/21